Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Director | April 28, 2011 | April 28, 2011 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date April 28, 2011 · Filed April 28, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 97,679 |
Reported balance
After 2011-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2011-04-28 · Grant · Acquired 5,500 · Balance 97,679 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby SLAT | 5,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,162 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,162 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $607.35 | $121,470.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 12 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on July 1, 2020 at prices ranging from $607.10 to $607.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $624.19 | $3,745.14 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 11 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $623.07 | $62,307.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 10 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $616.49 | $123,298.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 9 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,349 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $615.23 | $61,523.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 8 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,549 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $609.51 | $121,902.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,649 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on July 1, 2020 at prices ranging from $609.22 to $609.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 319 | $608.59 | $194,140.21 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 6 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,849 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 319 shares of Company stock on July 1, 2020 at prices ranging from $608.14 to $609.12. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 401 | $605.78 | $242,917.78 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 401 shares of Company stock on July 1, 2020 at prices ranging from $605.25 to $606.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 960 | $604.82 | $580,627.20 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,569 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 960 shares of Company stock on July 1, 2020 at prices ranging from $604.16 to $605.03. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 627 | $603.39 | $378,325.53 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,529 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 627 shares of Company stock on July 1, 2020 at prices ranging from $602.95 to $603.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2020 at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $601.70 | $60,170.00 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,156 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,613 | $413.33 | $1,493,361.29 |
DisclosureSEC source: 0001708138-20-000082 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 13, 2020 Filed Sep 23, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000106 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,349 Read SEC document |
| May 07, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,809 | $562.00 | $1,016,658.00 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,220 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · derivative · entry 9 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,610 Underlying: Common Stock · 5,220 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 250 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · derivative · entry 8 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 123 | $555.77 | $68,359.71 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,452 Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 250 | $273.67 | $68,417.50 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,538 | $555.77 | $1,966,314.26 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,220 | $376.69 | $1,966,321.80 |
DisclosureSEC source: 0001237899-20-000018 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-20-000011 · edgardoc.xml · derivative · entry 6 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 2,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 44 | $419.03 | $18,437.32 |
DisclosureSEC source: 0001237899-20-000011 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,956 | $419.00 | $819,564.00 |
DisclosureSEC source: 0001237899-20-000011 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $273.67 | $547,340.00 |
DisclosureSEC source: 0001237899-20-000011 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001237899-20-000004 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000004 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-19-000034 · edgardoc.xml · derivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 4,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,585 | $374.86 | $594,153.10 |
DisclosureSEC source: 0001237899-19-000034 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 1,585 shares of Company stock on December 13, 2019 at prices ranging from $374.81 to $374.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,400 | $373.91 | $523,474.00 |
DisclosureSEC source: 0001237899-19-000034 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,908 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 1,400 shares of Company stock on December 13, 2019 at prices ranging from $373.73 to $374.21. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,015 | $372.75 | $378,341.25 |
DisclosureSEC source: 0001237899-19-000034 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,308 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,015 shares of Company stock on December 13, 2019 at prices ranging from $372.56 to $373.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,000 | $273.67 | $1,094,680.00 |
DisclosureSEC source: 0001237899-19-000034 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-19-000012 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 4,500 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-19-000012 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,349 Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,500 | $349.00 | $1,570,500.00 |
DisclosureSEC source: 0001708138-19-000012 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,500 | $273.67 | $1,231,515.00 |
DisclosureSEC source: 0001708138-19-000012 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001237899-19-000006 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000006 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · derivative · entry 10 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 Underlying: Common Stock · 2,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 260 | $395.42 | $102,809.20 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 260 shares of Company stock on September 27, 2018 at prices ranging from $395.18 to $395.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 40 | $394.43 | $15,777.20 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 6 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $393.49 | $118,047.00 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on September 27, 2018 at prices ranging from $393.41 to $393.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 410 | $392.37 | $160,871.70 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 410 shares of Company stock on September 27, 2018 at prices ranging from $392.00 to $392.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 601 | $391.38 | $235,219.38 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 601 shares of Company stock on September 27, 2018 at prices ranging from $391.00 to $391.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 389 | $390.23 | $151,799.47 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,611 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 389 shares of Company stock on September 27, 2018 at prices ranging from $390.00 to $390.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $273.67 | $547,340.00 |
DisclosureSEC source: 0001237899-18-000016 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 22, 2018 Filed Aug 23, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001708138-18-000017 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 22, 2018 Filed Aug 23, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,500 | $380.49 | $570,735.00 |
DisclosureSEC source: 0001708138-18-000017 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 22, 2018 Filed Aug 23, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,500 | $177.82 | $266,730.00 |
DisclosureSEC source: 0001708138-18-000017 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2018 Filed Aug 23, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-18-000017 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,349 Read SEC document |
| March 19, 2018 Filed Aug 23, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-18-000017 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by SLAT Disclosed balance after: 5,000 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.